Price T Rowe Associates Inc. MD Has $138,000 Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC)

Price T Rowe Associates Inc. MD reduced its position in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 90.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 38,143 shares of the company's stock after selling 353,861 shares during the period. Price T Rowe Associates Inc. MD owned 0.05% of C4 Therapeutics worth $138,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in CCCC. Hennion & Walsh Asset Management Inc. increased its stake in shares of C4 Therapeutics by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 227,147 shares of the company's stock valued at $818,000 after buying an additional 34,783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of C4 Therapeutics in the 4th quarter valued at $54,000. Rhumbline Advisers grew its stake in shares of C4 Therapeutics by 4.6% during the fourth quarter. Rhumbline Advisers now owns 100,015 shares of the company's stock worth $360,000 after purchasing an additional 4,366 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of C4 Therapeutics during the fourth quarter worth $83,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of C4 Therapeutics by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 486,366 shares of the company's stock worth $1,751,000 after purchasing an additional 3,437 shares during the period. 78.81% of the stock is owned by institutional investors and hedge funds.

C4 Therapeutics Stock Up 0.7%

Shares of C4 Therapeutics stock traded up $0.01 during trading on Friday, reaching $1.38. 453,269 shares of the company were exchanged, compared to its average volume of 1,390,303. C4 Therapeutics, Inc. has a twelve month low of $1.09 and a twelve month high of $7.66. The business has a 50-day moving average price of $1.52 and a 200-day moving average price of $2.95. The firm has a market capitalization of $97.99 million, a price-to-earnings ratio of -0.81 and a beta of 3.10.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.11. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The business had revenue of $7.20 million during the quarter, compared to analysts' expectations of $3.54 million. On average, equities research analysts forecast that C4 Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, UBS Group raised C4 Therapeutics to a "hold" rating in a research note on Friday, February 14th.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.